TBX2

Across TCGA pan-cancer cohorts, TBX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBX2 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TBX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBX2 expression acts as an unfavorable survival marker.

MESO, LUSC, and OV are the cancer types where TBX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	II,III,IV	0.071	0.572	<.001	24	view →
LUSC	DFS	Median	All	0.140	0.797	<.001	15	view →
OV	OS	Median	II,III,IV	0.324	0.691	.049	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBX2–MESO (OS)

Open the MESO breakdown →